Literature DB >> 28398846

Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).

Joanne L Blum1, Patrick J Flynn1, Greg Yothers1, Lina Asmar1, Charles E Geyer1, Samuel A Jacobs1, Nicholas J Robert1, Judith O Hopkins1, Joyce A O'Shaughnessy1, Chau T Dang1, Henry Leonidas Gómez1, Louis Fehrenbacher1, Svetislava J Vukelja1, Alan P Lyss1, Devchand Paul1, Adam M Brufsky1, Jong-Hyeon Jeong1, Linda H Colangelo1, Sandra M Swain1, Eleftherios P Mamounas1, Stephen E Jones1, Norman Wolmark1.   

Abstract

Purpose Docetaxel and cyclophosphamide (TC) was superior to doxorubicin and cyclophosphamide (AC) in a trial in early breast cancer. However, activity of TC relative to AC regimens with a taxane (TaxAC) is unknown. Methods In a series of three adjuvant trials, women were randomly assigned to TC for six cycles (TC6) or to a standard TaxAC regimen. US Oncology Research (USOR) 06-090 compared TC6 with docetaxel, doxorubicin, and cyclophosphamide (TAC6). National Surgical Adjuvant Breast and Bowel Project (NSABP) B-46-I/USOR 07132 compared TC6, TAC6, or TC6 plus bevacizumab. NSABP B-49 compared TC6 with several standard AC and taxane combination regimens. Before any analysis of individual trials, a joint efficacy analysis of TC versus the TaxAC regimens was planned, with invasive disease-free survival (IDFS) as the primary end point. Patients who received TC6 plus bevacizumab on NSABP B-46-I/USOR 07132 were not included. A hazard ratio (HR) from a stratified Cox model that exceeded 1.18 for TC6 versus TaxAC was predefined as inferiority for TC6. The prespecified interim monitoring plan was to report for futility if the HR was > 1.18 when 334 IDFS events were observed (50% of 668 events required for definitive analysis). Results A total of 2,125 patients were randomly assigned to receive TC6 regimens and 2,117 patients were randomly assigned to receive TaxAC regimens. The median follow-up time was 3.3 years. There were 334 IDFS events, and the HR for TC6 versus TaxAC was 1.202 (95% CI, 0.97 to 1.49), which triggered early reporting for futility. The 4-year IDFS was 88.2% for TC6 and was 90.7% for TaxAC ( P = .04). Tests for treatment interaction by protocol, hormone receptor status, and nodal status were negative. Conclusion The TaxAC regimens improved IDFS in patients with high-risk human epidermal growth factor receptor 2-negative breast cancer compared with the TC6 regimen.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28398846      PMCID: PMC5549453          DOI: 10.1200/JCO.2016.71.4147

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  16 in total

1.  Stopping when the experimental regimen does not appear to help.

Authors:  S Wieand; G Schroeder; J R O'Fallon
Journal:  Stat Med       Date:  1994 Jul 15-30       Impact factor: 2.373

2.  Adjuvant docetaxel for node-positive breast cancer.

Authors:  Miguel Martin; Tadeusz Pienkowski; John Mackey; Marek Pawlicki; Jean-Paul Guastalla; Charles Weaver; Eva Tomiak; Taher Al-Tweigeri; Linnea Chap; Eva Juhos; Raymond Guevin; Anthony Howell; Tommy Fornander; John Hainsworth; Robert Coleman; Jeferson Vinholes; Manuel Modiano; Tamas Pinter; Shou C Tang; Bruce Colwell; Catherine Prady; Louise Provencher; David Walde; Alvaro Rodriguez-Lescure; Judith Hugh; Camille Loret; Matthieu Rupin; Sandra Blitz; Philip Jacobs; Michael Murawsky; Alessandro Riva; Charles Vogel
Journal:  N Engl J Med       Date:  2005-06-02       Impact factor: 91.245

3.  Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.

Authors:  Stephen E Jones; Michael A Savin; Frankie Ann Holmes; Joyce A O'Shaughnessy; Joanne L Blum; Svetislava Vukelja; Kristi J McIntyre; John E Pippen; James H Bordelon; Robert Kirby; John Sandbach; William J Hyman; Pankaj Khandelwal; Angel G Negron; Donald A Richards; Stephen P Anthony; Robert G Mennel; Kristi A Boehm; Walter G Meyer; Lina Asmar
Journal:  J Clin Oncol       Date:  2006-12-01       Impact factor: 44.544

4.  Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

Authors:  Eleftherios P Mamounas; John Bryant; Barry Lembersky; Louis Fehrenbacher; Scot M Sedlacek; Bernard Fisher; D Lawrence Wickerham; Greg Yothers; Atilla Soran; Norman Wolmark
Journal:  J Clin Oncol       Date:  2005-05-16       Impact factor: 44.544

5.  Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up.

Authors:  G Bonadonna; P Valagussa; A Moliterni; M Zambetti; C Brambilla
Journal:  N Engl J Med       Date:  1995-04-06       Impact factor: 91.245

6.  HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.

Authors:  Alessandra Gennari; Maria Pia Sormani; Paolo Pronzato; Matteo Puntoni; Mariantonietta Colozza; Ulrich Pfeffer; Paolo Bruzzi
Journal:  J Natl Cancer Inst       Date:  2007-12-25       Impact factor: 13.506

7.  Ten-year results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trial evaluating the use of L-phenylalanine mustard (L-PAM) in the management of primary breast cancer.

Authors:  B Fisher; E R Fisher; C Redmond
Journal:  J Clin Oncol       Date:  1986-06       Impact factor: 44.544

8.  Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

Authors:  I Craig Henderson; Donald A Berry; George D Demetri; Constance T Cirrincione; Lori J Goldstein; Silvana Martino; James N Ingle; M Robert Cooper; Daniel F Hayes; Katherine H Tkaczuk; Gini Fleming; James F Holland; David B Duggan; John T Carpenter; Emil Frei; Richard L Schilsky; William C Wood; Hyman B Muss; Larry Norton
Journal:  J Clin Oncol       Date:  2003-03-15       Impact factor: 44.544

9.  Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.

Authors:  Sandra M Swain; Gong Tang; Charles E Geyer; Priya Rastogi; James N Atkins; Paul P Donnellan; Louis Fehrenbacher; Catherine A Azar; André Robidoux; Jonathan A Polikoff; Adam M Brufsky; David D Biggs; Edward A Levine; John L Zapas; Louise Provencher; Donald W Northfelt; Soonmyung Paik; Joseph P Costantino; Eleftherios P Mamounas; Norman Wolmark
Journal:  J Clin Oncol       Date:  2013-08-12       Impact factor: 44.544

10.  Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.

Authors:  R Peto; C Davies; J Godwin; R Gray; H C Pan; M Clarke; D Cutter; S Darby; P McGale; C Taylor; Y C Wang; J Bergh; A Di Leo; K Albain; S Swain; M Piccart; K Pritchard
Journal:  Lancet       Date:  2011-12-05       Impact factor: 79.321

View more
  79 in total

Review 1.  Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.

Authors:  Tessa G Steenbruggen; Mette S van Ramshorst; Marleen Kok; Sabine C Linn; Carolien H Smorenburg; Gabe S Sonke
Journal:  Drugs       Date:  2017-08       Impact factor: 9.546

2.  Management of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific Approach.

Authors:  Jennifer Y Sheng; Cesar A Santa-Maria; Neha Mangini; Haval Norman; Rima Couzi; Raquel Nunes; Mary Wilkinson; Kala Visvanathan; Roisin M Connolly; Evanthia T Roussos Torres; John H Fetting; Deborah K Armstrong; Jessica J Tao; Lisa Jacobs; Jean L Wright; Elissa D Thorner; Christine Hodgdon; Samantha Horn; Antonio C Wolff; Vered Stearns; Karen L Smith
Journal:  JCO Oncol Pract       Date:  2020-06-30

3.  Personalized Decision Making in Early Stage Breast Cancer: Applying Clinical Prediction Models for Anthracycline Cardiotoxicity and Breast Cancer Mortality Demonstrates Substantial Heterogeneity of Benefit-Harm Trade-off.

Authors:  Jenica N Upshaw; Robin Ruthazer; Kathy D Miller; Susan K Parsons; John K Erban; Anne M O'Neill; Biniyam Demissei; George Sledge; Lynne Wagner; Bonnie Ky; David M Kent
Journal:  Clin Breast Cancer       Date:  2019-05-02       Impact factor: 3.225

4.  Double Trouble: Contralateral Breast Cancer Risk Management in the Modern Era.

Authors:  Kevin J Cheung; Nancy E Davidson
Journal:  J Natl Cancer Inst       Date:  2019-07-01       Impact factor: 13.506

5.  Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial.

Authors:  Aman U Buzdar; Vera J Suman; Funda Meric-Bernstam; Ann Marilyn Leitch; Matthew J Ellis; Judy C Boughey; Gary W Unzeitig; Melanie E Royce; Kelly K Hunt
Journal:  JAMA Oncol       Date:  2019-01-01       Impact factor: 31.777

6.  Biolayer interferometry provides a robust method for detecting DNA binding small molecules in microbial extracts.

Authors:  Ross D Overacker; Birte Plitzko; Sandra Loesgen
Journal:  Anal Bioanal Chem       Date:  2020-11-25       Impact factor: 4.142

Review 7.  Early stage triple negative breast cancer: Management and future directions.

Authors:  Lubna N Chaudhary
Journal:  Semin Oncol       Date:  2020-05-25       Impact factor: 4.929

8.  Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population-based study among older breast cancer patients.

Authors:  Aron S Rosenstock; Jiangong Niu; Sharon H Giordano; Hui Zhao; Antonio C Wolff; Mariana Chavez-MacGregor
Journal:  Cancer       Date:  2017-12-13       Impact factor: 6.860

Review 9.  Anthracycline Use for Early Stage Breast Cancer in the Modern Era: a Review.

Authors:  Sakshi Jasra; Jesus Anampa
Journal:  Curr Treat Options Oncol       Date:  2018-05-11

Review 10.  Landmark trials in the medical oncology management of early stage breast cancer.

Authors:  Whitney Hensing; Cesar A Santa-Maria; Lindsay L Peterson; Jennifer Y Sheng
Journal:  Semin Oncol       Date:  2020-08-30       Impact factor: 4.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.